• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Insulet touts results from Omnipod 5 study, expects launch this year

March 22, 2021 By Sean Whooley

InsuletInsulet (NSDQ:PODD) touted positive results from the first pivotal trial for its Omnipod 5 automated insulin delivery system.

Omnipod 5 is the world’s first tubeless, wearable system designed to continuously adapt insulin delivery based on glucose levels and trends, according to a news release.

Acton, Mass.-based Insulet said the device, which has FDA breakthrough device designation, significantly improved time in range and reduced Hba1c in children, adolescents and adults between age six and 70 with Type 1 diabetes. Insulet expects to launch the device in a limited release in the first half of this year.

 

Insulet CEO Shacey Petrovic explains how Insulet is switching diabetes patients to pods on a recent episode of the DeviceTalks Weekly Podcast.

 

The study observed 128 adults and adolescents between 14 and 70, then 112 children between six and 13.9 years old, all using the Omnipod 5 at home for a period of three months after a 14-day period using their standard therapy, whether that be pump therapy or multiple daily injections.

Omnipod 5 delivered a significant increase in time in range in adults and adolescents, increasing from 65% to 74%, or a difference of 2.2 hours per day, plus an overall reduction of HbA1c from 7.16% to 6.78%. Participants also saw a decrease in mean glucose from 161 to 154 mg/dL, with the median time below 70 mg/dL improving from 2% to 1.1%.

In the children group, time in range went up from 53% to 68%, marking a change of 3.7 more hours per day in the target range. HbA1c improved from 7.67% to 6.99%, and mean glucose level decreased from 183 to 160 mg/dL.

Almost all study participants (98%) completed the study and virtually all of them opted to continue use of the Omnipod 5 during an extension phase of the study.

“Our team has been committed to developing a hybrid closed-loop insulin delivery system to advance the treatment of insulin-dependent diabetes,” Insulet SVP & medical director Trang Ly said in the release. “Our pivotal study has achieved remarkable improvement in glucose control, evidenced by impressive reduction in HbA1c and improved time in range, together with the lowest rates of hypoglycemia.

“We are incredibly proud of these results, which demonstrate the system is safe and effective across a wide range of age groups. This is another step forward in our mission to simplify life for people with diabetes.”

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring Tagged With: Insulet

IN CASE YOU MISSED IT

  • Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS